Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SASCIA postneoadjuvant sacituzumab govitecan study in HER2-negative breast cancer
2023-510390-33-00Phase 3Authorised
- Sponsor
- GBG Forschungs
- Start
- Oct 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Invasive disease-free survival. Planned start Oct 2020; status: authorised.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-510390-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510390-33-00.